✦ LIBER ✦

Minimizing the non-extrapyramidal side-effects of antipsychotics

✍ Scribed by N. A. Keks

Book ID: 114785634
Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 691 KB
Volume: 94
Category: Article
ISSN: 0001-690X
DOI: 10.1111/j.1600-0447.1996.tb05944.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

On the extrapyramidal side-effects of an

On the extrapyramidal side-effects of antipsychotics with combined dopamine and 5-HT-blocking effects

✍ Leo Sher 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Extrapyramidal motor side-effects of fir

Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs

✍ Peluso, M. J.; Lewis, S. W.; Barnes, T. R. E.; Jones, P. B. 📂 Article 📅 2012 🏛 The Royal College of Psychiatrists 🌐 English ⚖ 319 KB

Increased risk of extrapyramidal side-ef

Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy

✍ R. M. Carnahan; B. C. Lund; P. J. Perry; E. A. Chrischilles 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

Modulation of antipsychotic-induced extr

Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders

✍ Ayaka Tatara; Saki Shimizu; Noriyuki Shin; Maho Sato; Tomone Sugiuchi; Junta Ima 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 640 KB

Extrapyramidal Side Effects of Antipsych

Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome

✍ Rajiv Tandon; Michael D. Jibson 📂 Article 📅 2002 🏛 American Academy of Clinical Psychiatrists 🌐 English ⚖ 454 KB

BW234: A nondopamine receptor-blocking a

BW234: A nondopamine receptor-blocking antipsychotic drug without extrapyramidal side effects?

✍ Dr. Jonathan Davidson; Anthony Dren; Robert Miller; Paul Manberg; Clinton Kilts; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB

Based on studies in animals and in healthy human volunteers, it was predicted that the carbazole compound BW234U would have antipsychotic effects in patients without producing concomitant extrapyramidal effects. The compound was administered to 22 inpatients with schizophrenia in an open, dose-rangi